HIV Infections D015658

Related MeSH Hierarchy (7)

Diseases [C] » Infections [C01] » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections

Diseases [C] » Infections [C01] » Virus Diseases » Sexually Transmitted Diseases, Viral » HIV Infections

Diseases [C] » Immune System Diseases [C20] » Immunologic Deficiency Syndromes » HIV Infections

Diseases [C] » Infections [C01] » Communicable Diseases » Blood-Borne Infections » HIV Infections

Description

Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).   MeSH

Hierarchy View

Subtype Terms (11)

AIDS Dementia Complex
21 drugs (16 approved, 5 experimental)

AIDS-Related Complex
3 approved drugs

AIDS-Related Opportunistic Infections
8 approved drugs

HIV-Associated Lipodystrophy Syndrome
31 drugs (28 approved, 3 experimental)

HIV Enteropathy
1 approved drug

HIV Seropositivity
30 drugs (21 approved, 9 experimental)

HIV Wasting Syndrome
8 drugs (7 approved, 1 experimental)


Phase 4 Indicated Drugs (159)

Phase 3 Indicated Drugs (96)

Phase 2 Indicated Drugs (265)

Phase 1 Indicated Drugs (338)

diethylhomospermine

digoxin (lanoxin)

diltiazem (cardizem)

dinitrochlorobenzene

diphtheria toxoid

dmlt

dna-c2

dna con-s env

dna mosaic env

dna mosaic-tre

dna nat-b env

ebt-101

efineptakin alpha

env 2-3

env (a,b,c,a/e)/gag (c) dna vaccine

env-c plasmid dna

envdna

envpro

eod-gt8 60mer

ep1090

ep-1233

ep hiv-1043

ep hiv-1090

erlotinib (tarceva)

etanercept (enbrel)

euphorbia kansui extract

f105

faldaprevir

fluorodopa (fluorodopa F18)

ft538

gemfibrozil (lopid)

genevax il-12-4532

geo-d02

geo-d03 dna vaccine

gla-af

gla-lsq

gla-se

glycine

glycoprotein 140

gp120 (a,b,c,a/e) protein vaccine

gp120w61d

gp145 c.6980 vaccine

gp160 mn/lai-2

gp160 vaccine

griffithsin

gs-5894

gsk3732394

gsk3739937

gw 695634

gx-12

he2000

hiv-1 c4-v3 polyvalent peptide vaccine

hiv-1 delta-v2 env vaccine

hiv-1 gag dna

hiv-1 gp 160

hiv-1 nef/tat/vif, env pdna vaccine

hiv-1 peptide immunogen, multivalent

hiv-1 peptide vaccine, microparticulate monovalent

hiv-1 recombinant ad5 vaccine

hiv-1 specific car-t cells

hiv-1 tat/delta-v2 env combined vaccine

hiv-1 tat vaccine

hiv-1 trimeric gp140 env

hivac-1e

hivax

hiv ctl mep

hiv dna vaccine

hiv gag-pol antigens

hiv glycoprotein 140

hiv gp120/neftat/as02a vaccine

hivis dna vaccine

hiv lfn-p24

hiv-mag

hiv mrna

hiv p17/p24:ty-vlp

hiv-specific cd8 cells

hiv-specific t cell

hsp70 conjugate vaccine

human immunodeficiency virus glycoprotein 140 vaccine

hyaluronidase (human recombinant) (Hylenex)

hydroxyethyl starch (voluven)

hypericin (sgx301)

hyrdrogen ion

ibrutinib (imbruvica)

idx899

Other Experimental Indicated Drugs (68)


Organization Involved with Phase 4 Indications (222)

Aalborg University

Aarhus University

AbbVie

AIDS Clinical Trials Group

AIDS Committee of Toronto

American Association of Colleges of Pharmacy

AmFAR

Badalona Hospital Germans Trias i Pujol

Bamrasnaradura Infectious Diseases Institute

Barry M. Rodwick, M. D.

Bausch Health Companies

Baylor University

Bill and Melinda Gates Foundation

B.I. South Africa (Pty.) Ltd.

Boston University

Brown University

California Collaborative Treatment Group

California HIV/AIDS Research Program

Canadian AIDS Treatment Information Exchange

Cantonal Hospital of St. Gallen

Case Western Reserve University

Catholic University of Sacred Heart, Rome

Centers for Disease Control and Prevention (CDC)

Chinese Academy of Medical Sciences

Chulalongkorn University

CIHR Canadian HIV Trials Network

Clinical Trial Agency of HIV Study Group

Clinique du Quartier Latin

Columbia University

Community Research Initiative of New England

Cornell University

Department of Foreign Affairs, Ireland

Department of Veteran Affairs

Drugs for Neglected Diseases Initiative

Duke University

East Carolina University

Emory University

Erasmus University Rotterdam

Federal University of Rio de Janeiro

Fenway Community Health

FHI 360

Foundation for Cardiovascular Research, Zurich

French Development Agency

French National Agency for Research on AIDS and Viral Hepatitis

Fudan University

Fundacio Lluita Contra la SIDA

Fundacion Huesped

Fundación Pública Andaluza

Fundacion SEIMC-GESIDA

Fundación Vía Libre

George Mason University

George Washington University

Government of Brazil

Government of China

Government of Italy

Government of Mexico

Government of Spain

Government of Taiwan

Government of Thailand

Guangdong Provincial Maternal and Child Health Hospital

Guangxi Medical University

Harvard University

Hassle Free Clinic

Health Canada

Helios Salud, Buenos Aires, Argentina

Hennepin Healthcare

Henry Ford Health System

HIV-NAT Thai Red Cross AIDS Research Center

Holdsworth House Medical Practice

Hospital de Calella

Hospital de Sant Pau i Santa Tecla de Tarragona

Hospital Federal dos Servidores do Estado

Hospital General Universitario Gregorio Marañon

Hospital Joan XXIII de Tarragona, Tarragona, Spain

Hospital San Carlos, Madrid

Hospital San Jaime de Calella

Hospital Sant Jaume de Calella

Hospital Universitario Ramon y Cajal

Howard University

Indiana University

Infectious Disease Consultants, PLLC

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Instituto de Medicina Integral Professor Fernando Figueira

Instituto Mexicano del Seguro Social

Instituto Nacional de Ciencias Medicas y Nutricion

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Instituto Nacional de Enfermedades Respiratorias

Instituto Nacional de la Nutrición Salvador Zubiran

Integrium

International Antiviral Therapy Evaluation Center (IATEC)

IrsiCaixa

I-Shou University

Janssen Pharmaceutica NV

Johns Hopkins University

Joint Clinical Research Centre, Kampala, Uganda

Kennemer Gasthuis

KhonKaen University

Laboratorios Nacionales de Biológicos y Reactrivos

Leiden University

Leyenburg Hospital

Luigi Sacco University Hospital

Makerere University

Maple Leaf Medical Clinic

Mater Misericordiae University Hospital

Maternal and Child Health Hospital of Yunan Province

McGill University

Medecins Sans Frontieres

Medical Research Council

Medical Research Council-UVRI Uganda Research Unit on AIDS

Napo Pharmaceuticals

National Cancer Institute (NCI)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Child Health and Human Development (NICHD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute of Mental Health (NIMH)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute on Drug Abuse (NIDA)

National Institutes of Health (NIH)

National Taiwan University

National University of Ireland

NHS Health Technology Assessment Programme

Novo Nordisk

Oklahoma State University

OLVG hospital, Amsterdam

Ontario HIV Treatment Network

Onze Lieve Vrouw Hospital

Osakidetza

Oswaldo Cruz Foundation

Peter J. Ruane, M.D.

PETHEMA Foundation

Pierre and Marie Curie University

PR-CoNCRA

Projeto Praça Onze

Pronova BioPharma

Puerto Rico Community Network for Clinical Research on AIDS

Rijnstate Hospital

Rodwick, Barry M., M.D.

Rush University

Ruth M. Rothstein CORE Center

Ryerson University

Sanquin

Sao Paulo State University

Sichuan University

Slotervaart Hospital

Sociedad Andaluza de Enfermedades Infecciosas

Stanford University

Stellenbosch University

St. Hope Foundation

St Stephens Aids Trust

St. Vincent's Hospital-Manhattan

Swiss HIV Cohort Study

Swiss National Science Foundation

Sydney Hospital

Taipei Veteran General hospital

Taoyuan General Hospital

Temple University

The American Society of Tropical Medicine and Hygiene

The Campbell Foundation

The Fenway Institute

The HIV Netherlands Australia Thailand Research Collaboration

Therapeutic Concepts

Trimeris

Trinity College Dublin

Tsinghua University

Tufts University

UBS Optimus Foundation

Organization Involved with Phase 3 Indications (171)

Organization Involved with Phase 2 Indications (202)

Organization Involved with Phase 1 Indications (122)

Organization Involved with Other Experimental Indications (58)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.